Chugai's osteoporosis agent Edirol launched in China

Japanese drug major Chugai Pharmaceutical’s (TYO: 4519) Chinese subsidiary has launched Edirol (eldecalcitol) in China for the treatment of postmenopausal osteoporosis.

Edirol is an active vitamin D3 derivative created by Chugai. The product obtained regulatory approval from the China National Medical Products Administration (NMPA) on December 2020.

“We are very pleased that Edirol, an osteoporosis agent created by Chugai, has been launched in China. Edirol has long been recognized in Japan as a base drug for the treatment of osteoporosis, used by more than 10 million patients to date,” said Dr Osamu Okuda, president and chief executive of Chugai, which is majority-owned by Switzerland’s Roche (ROG: SIX). “Prevention of fractures is important for the well-being of patients with osteoporosis. Aiming to contribute to the osteoporosis treatment in China, Chugai Pharma China, a group company which leads our business in China, will provide information of Edirol in collaboration with Roche China,” he added